List of Excipients in Branded Drug SORINE

« Back to Dashboard

Generic Drugs Containing SORINE

Company	Ingredient	NDC	Excipient
Upsher-Smith Laboratories Inc	sotalol hydrochloride	0245-0012	CELLULOSE, MICROCRYSTALLINE
Upsher-Smith Laboratories Inc	sotalol hydrochloride	0245-0012	LACTOSE MONOHYDRATE
Upsher-Smith Laboratories Inc	sotalol hydrochloride	0245-0012	MAGNESIUM STEARATE
Upsher-Smith Laboratories Inc	sotalol hydrochloride	0245-0012	SILICON DIOXIDE
Upsher-Smith Laboratories Inc	sotalol hydrochloride	0245-0012	STARCH, CORN
Upsher-Smith Laboratories Inc	sotalol hydrochloride	0245-0012	STEARIC ACID

What are the Most Frequently-Used Excipients in SORINE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
2	SILICON DIOXIDE
2	STARCH, CORN
2	STEARIC ACID

Sorine Excipient Strategy and Commercial Opportunities for Sotalol Hydrochloride

Last updated: October 6, 2026

Sorine is an oral sotalol hydrochloride product used for ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or atrial flutter. Its commercial value is no longer based on brand exclusivity. The opportunity is in differentiated generic formulations, adherence-focused dosage forms, hospital-to-home products, and controlled-release or liquid presentations that address dosing, renal adjustment, swallowing, and monitoring requirements.

Sotalol is a high-risk antiarrhythmic with dose-dependent QT prolongation and a narrow practical safety margin. Excipient selection must protect dissolution consistency, dose uniformity, stability, and renal-dose flexibility. A formulation that changes exposure or absorption materially can create regulatory and clinical risk.

What is Sorine and which active ingredient does it contain?

Sorine contains sotalol hydrochloride, a nonselective beta-adrenergic blocker with Class III antiarrhythmic activity. The product is supplied as immediate-release oral tablets in multiple strengths, allowing titration and renal dose adjustment.

Attribute	Sorine
Active ingredient	Sotalol hydrochloride
Dosage form	Immediate-release tablet
Main indications	Ventricular arrhythmias; maintenance of sinus rhythm in atrial fibrillation or atrial flutter
Typical strengths	80 mg, 120 mg, 160 mg, and 240 mg tablets
Administration	Oral
Key safety issue	QT prolongation and risk of torsades de pointes
Dose determinant	Renal function and QT interval
Regulatory category	Small-molecule prescription drug
Biosimilar exposure	None
Current commercial position	Genericized, mature market

The FDA label requires initiation or reinitiation under conditions that permit cardiac monitoring and assessment of creatinine clearance. Sotalol is eliminated primarily through the kidneys, making renal function central to dosing and formulation strategy.[1]

What excipients are commercially relevant in Sorine tablets?

The relevant excipient strategy for a sotalol tablet is conventional immediate-release oral solid dosage technology. The commercial objective is not complex delivery. It is reproducible dissolution across strengths, reliable tablet manufacture, chemical stability, and compatibility with generic bioequivalence requirements.

Public labeling for older Sorine presentations identifies conventional tablet excipients, but inactive-ingredient composition can vary by strength, manufacturer, and product version. Commercial developers should verify the target reference-listed drug presentation against the current FDA labeling and inactive-ingredient databases before finalizing a formulation.[2,3]

Core excipient functions

Formulation function	Candidate excipient classes	Commercial rationale
Dilution and tablet mass	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Supports manufacturability across 80 mg to 240 mg strengths
Binder	Povidone, hydroxypropyl cellulose, pregelatinized starch	Improves granule or tablet strength
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Promotes rapid immediate release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Opacifier or colorant	Titanium dioxide, iron oxides, approved pigments	Enables strength identification and packaging differentiation
Film coat	Hypromellose, polyethylene glycol, talc, pigments	Improves handling, identification, and swallowability

The highest-value excipient decisions concern disintegration and lubrication. Excessive hydrophobic lubrication can slow dissolution, while an overly aggressive disintegrant system can create friability, capping, or unstable tablet performance. These effects matter because sotalol products must demonstrate consistent exposure and dissolution across strengths.

How should an excipient strategy be designed for sotalol tablets?

The preferred base strategy is a robust immediate-release platform with a common manufacturing process across strengths.

Use a common formulation platform

A proportional or near-proportional formulation across 80 mg, 120 mg, 160 mg, and 240 mg strengths can simplify scale-up, validation, and postapproval manufacturing. A common platform also reduces the risk that one strength develops a distinct dissolution profile or stability problem.

The formulation should support:

• Rapid and reproducible disintegration.
• Low tablet-to-tablet weight variation.
• Adequate hardness without delayed drug release.
• Low friability during bottle or blister handling.
• Stable assay and impurity profile through shelf life.
• Clear strength differentiation to reduce medication errors.

Because sotalol dose selection is clinically consequential, tablet appearance should make strength confusion difficult. Color coding, debossing, distinct shape, and unit-dose packaging have greater commercial value than cosmetic differentiation alone.

Control excipient effects on bioavailability

Sotalol is highly water soluble, so dissolution is unlikely to be limited by intrinsic solubility under normal immediate-release conditions. The main risks are excipient-driven changes in wetting, disintegration, gastric transit, and release consistency.

Developers should pay particular attention to:

• High lubricant levels that retard wetting.
• Hydrophobic coatings that delay release.
• Excessive binder levels that create hard, slowly disintegrating tablets.
• Sugar alcohols or large polyol loads that may alter gastrointestinal tolerance.
• Cationic or anionic excipients that could create compatibility or process issues.
• Hygroscopic excipients that affect tablet hardness and stability.

A simple, low-risk excipient system is likely to have a stronger commercial profile than a novel composition that creates a new safety or bioequivalence question.

Build the formulation around renal dosing

Sotalol dosing is adjusted according to creatinine clearance. The formulation therefore needs a practical range of strengths rather than a single high-dose unit. A 40 mg strength, scored 80 mg tablet, or flexible multiparticulate product could support more granular dosing, but each option has regulatory and usability implications.

A 40 mg product could improve titration for patients with reduced renal function. It could also increase manufacturing complexity and inventory requirements. A scored tablet may be more economical, but dose-splitting performance must be controlled and supported by labeling.

What commercial opportunities exist for Sorine and generic sotalol?

The strongest opportunities are differentiated oral presentations rather than a conventional unbranded tablet.

Opportunity ranking

Opportunity	Commercial attractiveness	Main barrier
Standard generic tablets	Low to moderate	Price competition and multiple approved suppliers
40 mg titration strength	Moderate	Limited market size and dosing validation
Scored tablets	Moderate	Split-dose uniformity and labeling requirements
Oral solution	Moderate to high	Stability, taste, packaging, and dosing-device control
Pediatric or swallowing-friendly formulation	Moderate	Limited indication and clinical-use evidence
Unit-dose hospital packaging	Moderate	Contract access and pharmacy procurement economics
Modified-release product	High if clinically differentiated	Complex PK, safety, and clinical development
Sprinkle or multiparticulate capsule	Moderate	Dose uniformity and food-effect assessment
Combination product	Low to moderate	Clinical rationale and regulatory complexity

Oral solution and liquid-dose opportunities

An oral solution could address patients who cannot swallow tablets, patients receiving enteral nutrition, and selected pediatric or geriatric populations. The product would need:

• Accurate dosing at low volumes.
• A calibrated oral syringe.
• Palatable taste or effective taste masking.
• Chemical and microbiological stability.
• Container-closure compatibility.
• Clear storage instructions.
• A concentration that minimizes dosing errors.

Sotalol’s high water solubility supports a liquid-development rationale. The commercial limitation is that the principal labeled uses are adult cardiac indications, and initiation or dose changes still require monitoring. A liquid product would therefore expand administration options more than it would create a large untreated population.

Multiparticulate and sprinkle formulations

A capsule containing coated or uncoated multiparticulates could improve swallowing while preserving dose flexibility. The principal technical risk is that coating, particle size, and administration with soft food may alter release. For immediate-release sotalol, unnecessary functional coating should be avoided unless it provides a clear handling or taste advantage.

The most credible use case is a sprinkle product for patients with dysphagia or feeding-tube needs. Commercial uptake would depend on demonstrated compatibility with common foods and enteral administration methods.

Modified-release sotalol

A modified-release product could reduce dosing frequency, but it carries the highest development burden. Sotalol exposure is directly connected to QT prolongation, so an extended-release formulation must establish:

• Predictable exposure over the full dosing interval.
• No excessive peak concentration.
• Acceptable trough concentrations.
• Renal-dose flexibility.
• Food-effect control.
• Consistent performance in patients with reduced renal clearance.

A once-daily product could compete on adherence and convenience. The development program would likely require more than a routine generic bioequivalence approach, particularly if the pharmacokinetic profile differs materially from the immediate-release reference.

What FDA regulatory status and Orange Book issues affect Sorine?

Sorine is a small-molecule prescription product, not a biologic. Biosimilar regulation does not apply. Any follow-on product would generally use an abbreviated new drug application if it matches the reference product in active ingredient, dosage form, strength, route, labeling framework, and performance requirements.

The key regulatory pathways are:

Product concept	Likely FDA pathway
Conventional equivalent tablet	ANDA
New oral solution with substantial formulation differences	ANDA if reference-equivalent; otherwise 505(b)(2) may be relevant
Modified-release product	ANDA only if an applicable reference and equivalence pathway exists; otherwise 505(b)(2) or NDA
New indication or materially different clinical use	505(b)(2) or NDA
Combination product	ANDA or 505(b)(2), depending on the reference and active ingredients

Orange Book review should focus on the current reference-listed drug, active patents, exclusivity listings, therapeutic-equivalence codes, and approved dosage forms. Sorine’s historical brand position does not create a current barrier equivalent to a recently approved protected product. The principal commercial barriers are development cost, manufacturing quality, competitive pricing, and cardiac safety rather than brand patent exclusivity.[4]

Does Sorine have active patent protection?

The original sotalol compound and conventional immediate-release tablet technology are mature. Core compound protection and early formulation exclusivity expired long ago. Commercial analysis should not assume that historical Sorine or Betapace branding creates an active patent barrier.

A developer should still screen:

• Current Orange Book patent listings for the selected reference product.
• Later patents covering modified-release delivery.
• Device or packaging patents for liquid or unit-dose systems.
• Method-of-use patents directed to specific patient populations.
• Patent families covering salt forms, polymorphs, or manufacturing processes.

For a conventional generic tablet, the expected intellectual-property risk is low. For a new release profile or administration platform, patent risk becomes more relevant because the differentiation itself may be patentable.

Are there Paragraph IV challenges or generic litigation risks?

The conventional sotalol market is mature and has long included generic competition. Paragraph IV activity is therefore more relevant to later differentiated products than to the original Sorine tablet.

A new applicant should separate three risk categories:

1. Reference-product risk. Existing patents or exclusivity listed against the selected reference product.
2. Formulation risk. Patents covering release-control polymers, multiparticulates, oral-liquid stabilization, or taste masking.
3. Method-of-use risk. Patents claiming treatment regimens, patient subsets, or initiation protocols.

Litigation exposure is likely to be limited for a basic immediate-release tablet but can increase if a sponsor seeks to commercialize a once-daily or clinically differentiated product. A Paragraph IV certification may be commercially unnecessary where no relevant listed patents remain, but freedom-to-operate analysis should include unlisted patents and non-Orange-Book process rights.

What manufacturing and IP barriers affect sotalol formulation opportunities?

The chemistry of sotalol is not the primary barrier. The major barriers are quality-system execution and the clinical consequences of dose variability.

Manufacturing barriers

A commercial product must manage:

• Blend uniformity across multiple strengths.
• Tablet weight and hardness.
• Disintegration and dissolution control.
• Moisture sensitivity of selected excipients.
• Stability-indicating impurity methods.
• Packaging that protects against humidity.
• Accurate strength identification.
• Scored-tablet performance if dose splitting is claimed.

A direct-compression process could reduce cost and process steps, but it requires strong powder-flow and compressibility characteristics. Wet granulation may improve content uniformity and tablet robustness but adds drying, scale-up, and moisture-control requirements.

Intellectual-property barriers

A basic formulation is unlikely to support substantial patent protection. Stronger opportunities may come from:

• A validated once-daily release profile.
• A liquid formulation with extended stability.
• A low-volume concentrated solution.
• A taste-masked multiparticulate system.
• A dose-flexible tablet with demonstrated split accuracy.
• A packaging and administration system that reduces dosing errors.

Patent value depends on whether the formulation produces a clinically meaningful advantage that is difficult to design around. Broad claims covering common excipients are unlikely to provide durable protection.

How does Sorine compare with other sotalol products?

Sorine competes within the sotalol product group rather than against a single branded substitute. Betapace and Betapace AF are historically important reference products, while generic sotalol hydrochloride tablets provide price competition. The products may differ in labeling, strength availability, tablet appearance, manufacturer, and supply reliability.

Product type	Differentiation	Commercial position
Sorine immediate-release tablet	Established brand formulation	Mature, genericized
Betapace immediate-release product	Brand recognition and historical reference status	Limited price advantage after generic entry
Betapace AF	Atrial fibrillation-focused labeling and historical brand positioning	Narrower commercial role
Generic sotalol tablets	Low acquisition cost	Dominant volume strategy
New liquid or modified-release product	Administration or adherence advantage	Potential premium niche

The most defensible commercial strategy is to target a defined operational problem, such as swallowing difficulty, renal-dose titration, or inpatient unit-dose distribution. A tablet with the same strength and excipient profile as existing generics offers little room for pricing power.

What licensing deals or partnership models could support a Sorine opportunity?

Publicly visible licensing value for the legacy Sorine brand is limited. The more viable partnership models involve differentiated delivery or commercial infrastructure.

Potential structures include:

• Licensing a modified-release platform to a generic manufacturer.
• Contract development and manufacturing for an oral solution.
• Hospital-channel commercialization of unit-dose packaging.
• Co-development with a specialty cardiology company.
• Acquisition of an established sotalol ANDA with manufacturing rights.
• Regional licensing where supply reliability is weak.
• Technology transfer for taste masking or multiparticulate filling.

A partner would likely value regulatory readiness, stable manufacturing, and pharmacy-channel access more than legacy Sorine trademarks. The commercial case should therefore be built around product economics and supply reliability.

What generic launch scenarios exist for sotalol?

Standard generic launch

This is the lowest-risk scenario but also the least attractive economically. Multiple suppliers can compete on price, and pharmacy substitution limits brand differentiation.

Premium administration launch

An oral solution, sprinkle capsule, or smaller-dose tablet could obtain better margins if it solves a documented adherence or administration problem. The market is smaller, so manufacturing and distribution costs must remain low.

Modified-release launch

A once-daily product could command stronger commercial interest, but it requires a substantially larger regulatory and clinical investment. QT exposure, renal impairment, and food effects are central development questions.

Supply-reliability strategy

A manufacturer can compete without novel formulation technology by offering dependable supply, multiple strengths, tamper-evident packaging, and hospital-ready presentations. This strategy is particularly relevant where intermittent generic shortages affect procurement decisions.

What is the patent strength of the Sorine formulation estate?

The legacy immediate-release estate is weak as a barrier to entry because the product is mature, the active ingredient is established, and generic alternatives are available. The strongest protectable assets would be later-generation delivery systems.

Asset	Expected patent strength	Reason
Conventional immediate-release tablet	Low	Easy design-around and mature technology
Novel excipient combination alone	Low to moderate	Patentability and nonobviousness may be limited
Stable oral solution	Moderate	Stability and concentration claims may be defensible
Taste-masked multiparticulates	Moderate	Process and particle-engineering claims may narrow design-around
Modified-release system	Moderate to high	More technical differentiation, but greater prior-art exposure
Packaging and dose-control system	Moderate	Useful if linked to measurable error reduction
New clinical method of use	Variable	Scope depends on patent eligibility and claim specificity

Key Takeaways

• Sorine contains sotalol hydrochloride in an immediate-release oral tablet.
• The legacy brand has little remaining exclusivity value; conventional generic entry is established.
• Excipient strategy should prioritize rapid, reproducible release, dose uniformity, stability, and strength differentiation.
• The best commercial opportunities are oral solution, dose-flexible tablets, sprinkle formulations, unit-dose packaging, and potentially modified-release products.
• Sotalol’s renal elimination and QT-prolongation risk make exposure control more important than excipient novelty.
• A conventional tablet is a low-margin generic opportunity.
• A differentiated dosage form can create value, but regulatory and clinical requirements rise sharply when the release profile changes.
• Biosimilar risk is irrelevant because sotalol is a small molecule.
• Patent strength is weak for the legacy Sorine formulation and potentially stronger for later delivery technologies.

FAQs About Sorine Excipient Strategy and Commercial Opportunities

Can Sorine be reformulated as an oral solution?

Yes. Sotalol’s water solubility supports an oral-solution concept, but the product would require concentration control, palatability work, stability testing, microbiological controls, and an accurate dosing device.

Is a 40 mg sotalol tablet commercially attractive?

It may support renal-dose titration and lower-dose initiation, but the addressable market is narrower than for 80 mg and 120 mg tablets. Commercial viability depends on manufacturing cost and payer demand.

Does sotalol require a biosimilar development program?

No. Sotalol is a chemically synthesized small molecule. Follow-on products use generic-drug pathways rather than the biosimilar pathway.

Could a once-daily sotalol product receive premium pricing?

Potentially, if it demonstrates consistent exposure, acceptable QT safety, renal-dose flexibility, and a meaningful adherence advantage. The development burden would be materially higher than for an immediate-release generic.

Which excipient creates the greatest formulation risk in sotalol tablets?

The lubricant system is a major risk because excessive hydrophobic lubrication can slow wetting and dissolution. Binder level and disintegrant selection also require tight control to preserve immediate release.

References

1. U.S. Food and Drug Administration. (2009). Sorine (sotalol hydrochloride) tablets: Prescribing information. FDA.

2. National Library of Medicine. (n.d.). DailyMed: Sotalol hydrochloride tablet labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.